Ensign Peak Advisors
GMAB icon

Ensign Peak Advisors’s Genmab GMAB Stock Holding History

Ensign Peak Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,200
Closed -$692K – 1759
2023
Q2 		$692K Hold
18,200
– – ﹤0.01% 1507
2023
Q1 		$687K Hold
18,200
– – ﹤0.01% 1523
2022
Q4 		$771K Hold
18,200
– – ﹤0.01% 1374
2022
Q3 		$585K Hold
18,200
– – ﹤0.01% 1372
2022
Q2 		$591K Hold
18,200
– – ﹤0.01% 1383
2022
Q1 		$658K Sell
18,200
-28,394
-61% -$974K ﹤0.01% 1430
2021
Q4 		$1.84M Buy
+46,594
New +$1.94M ﹤0.01% 991

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ensign Peak Advisors's GMAB Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Genmab (GMAB) in Q3 2023, closing a stake of 18,200 shares — an estimated $692K sold.

Ensign Peak Advisors first reported a position in GMAB in Q4 2021 and held it in 7 quarters. The position peaked at $1.84M in Q4 2021. 233 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

  • Ensign Peak Advisors reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 18,200 Genmab shares in Q3 2023, an estimated $692K.
  • Ensign Peak Advisors first reported a position in Genmab in Q4 2021 and held it in 7 quarters.
  • Ensign Peak Advisors's Genmab position peaked at $1.84M in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.